Proposed inspection measures in China could have serious implications for foreign drug manufacturers
This article was originally published in SRA
China's State Food and Drug Administration is seeking feedback on proposed regulations for administering inspections of foreign drug manufacturers that, if adopted, will have serious implications for overseas companies that import or apply to import drugs to China1,2.
You may also be interested in...
The Pink Sheet’s list of EU centralized approvals of new active substances has been updated with two new products including Merck Sharp & Dohme's Ebola vaccine, Ervebo. The list, which contains information dating back to January 2018, includes brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).
The stakes are extremely high for companies called before EU or US regulators and scientific experts to answer queries about their new drug applications at the later stages of the review process. Consultant Kate Dion highlights to In Vivo helpful tips for companies facing this daunting situation.
The reimbursement deal will allow cystic fibrosis patients as young as two years of age to access Orkambi in France for the first time.